Literature DB >> 25764361

Clinical analysis of patients with primary ciliary dyskinesia in mainland China.

Yueqin Cao1,2, Changzhou Shao3, Yuanlin Song1, Chunxue Bai1, Lixian He1.   

Abstract

BACKGROUND AND AIMS: Primary ciliary dyskinesia (PCD) is a rare, genetic disorder featured with dysfunctional motility of cilia. Clinical presentations of PCD include situs inversus, repeated respiratory tract infections, otitis media, sinusitis and infertility. This study aims to provide clinical strategies on diagnosis and treatment of PCD.
METHODS: Clinical data of seven patients diagnosed as PCD in Zhongshan Hospital, Fudan University were analyzed. We also extracted data from other cases in mainland China from the China Academic Journals Full-Text Database by the end of 2012. A total of 127 cases of PCD were summarized and analyzed in this study.
RESULTS: Seven patients in Zhongshan Hospital, Fudan University were finally confirmed to have PCD. All of them had clinical history of recurrent respiratory infection. Imaging analysis showed varying degrees of bronchiectasis. Pulmonary function tests in four patients showed combined obstructive and restrictive patterns. Three cases were confirmed to have PCD by electron microscopy. We then further extracted information from literature for those 127 PCD patients in mainland China. All of them had chronic respiratory infection. Seven cases were complicated with recurrent otitis media and 15 cases were complicated with infertility. A total of 119 patients were diagnosed with situs inversus totalis (94%). Among those 127 patients, only 9 patients' diagnosis was confirmed by electron microscopy. Four patients received sinus resection, and one patient received pulmonary lobectomy due to recurrent hemoptysis. One patient died of massive hemoptysis.
CONCLUSIONS: Being a rare disease and easily confused with uncomplicated bronchiectasis, PCD diagnosis warrants particular attention. Recurrent respiratory infection, especially situs inversus could be the most important indicator of this disease.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  bronchiectasis; mainland China; misdiagnosis; primary ciliary dyskinesia; treatment

Mesh:

Year:  2015        PMID: 25764361     DOI: 10.1111/crj.12284

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  5 in total

Review 1.  Clinical and genetic spectrum of primary ciliary dyskinesia in Chinese patients: a systematic review.

Authors:  Bo Peng; Yong-Hua Gao; Jia-Qi Xie; Xiao-Wen He; Cong-Cong Wang; Jin-Fu Xu; Guo-Jun Zhang
Journal:  Orphanet J Rare Dis       Date:  2022-07-19       Impact factor: 4.303

2.  Collecting clinical data in primary ciliary dyskinesia- challenges and opportunities.

Authors:  Israel Amirav; Mary Roduta Roberts; Huda Mussaffi; Avigdor Mandelberg; Yehudah Roth; Revital Abitbul; Anthony Luder; Hannah Blau; Soliman Alkrinawi; Micha Aviram; Marta Ben-Ami; Moshe Rotschild; Lea Bentur; David Shoseyov; Malena Cohen-Cymberknoh; Eitan Kerem; Avraham Avital; Chaim Springer; Avigdor Hevroni; Husein Dabbah; Arnon Elizur; Elie Picard; Shmuel Goldberg; Joseph Rivlin; Galit Livnat; Moran Lavie; Nael Alias; Ruth Soferman; Heike Olbrich; Johanna Raidt; Julia Wallmeier; Claudius Werner; Niki T Loges; Heymut Omran
Journal:  F1000Res       Date:  2016-08-18

3.  Cilia distribution and polarity in the epithelial lining of the mouse middle ear cavity.

Authors:  Wenwei Luo; Hong Yi; Jeannette Taylor; Jian-Dong Li; Fanglu Chi; N Wendell Todd; Xi Lin; Dongdong Ren; Ping Chen
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

4.  Therapeutic outcomes of canal wall up mastoidectomy in combination with Type I tympanoplasty in otitis media.

Authors:  Liansheng Zhang
Journal:  Pak J Med Sci       Date:  2016 May-Jun       Impact factor: 1.088

5.  Novel dynein axonemal assembly factor 1 mutations identified using whole‑exome sequencing in patients with primary ciliary dyskinesia.

Authors:  Lei Zhou; Zhuozhe Li; Chunling Du; Cuicui Chen; Yingxin Sun; Liang Gu; Feng Zhou; Yuanlin Song
Journal:  Mol Med Rep       Date:  2020-10-06       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.